Sarcopenia Pipeline Insight
DelveInsight’s, “Sarcopenia – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Sarcopenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Sarcopenia is a progressive and generalized skeletal muscle disorder involving the accelerated loss of muscle mass and function that is associated with increased adverse outcomes, including falls, functional decline, frailty, and mortality. It occurs commonly as an age-related process in older people, influenced not only by contemporaneous risk factors but also by genetic and lifestyle factors operating across the life course. It can also occur in mid-life in association with a range of conditions.
Symptoms can include weakness and loss of stamina, which can interfere with physical activity. Reduced activity further shrinks muscle mass.
Diagnosing Sarcopenia with contemporary operational definitions requires assessments of muscle mass, muscle strength, and physical performance. Screening is recommended for both elderly patients and those with conditions that noticeably reduce physical function. The condition is highly prevalent in orthopedic patient populations and correlates with higher hospital costs and rates of falling, fracture, and mortality.
Although the exact levels differ slightly between published definitions, the disease has recently been included in the ICD-10. It can be adequately screened for in primary care, and assessment of the defining features should occur under the supervision of specialists to allow diagnosis. Treatments currently include resistance exercise, vitamin D supplementation and protein supplementation. Still, it is hoped that, with the advent of the ICD-10 definition, therapeutic trials and intervention development will gain momentum. Trials with various agents, including selective androgen receptor modulators and myostatin inhibitors, show promise as future treatment options. Moreover, increased awareness of Sarcopenia is of great importance to begin reaching consensus on diagnosis and to contribute to finding a cure for this condition.
The companies and academics are working to assess challenges and seek opportunities that could influence Sarcopenia R&D. The therapies under development are focused on novel approaches to treat/improve Sarcopenia.
Sarcopenia Emerging Drugs Chapters
This segment of the Sarcopenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sarcopenia Emerging Drugs
Sarconeos (BIO101): Biophytis
Biophytis’ lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases. Preclinical data demonstrated that Sarconeos (BIO101) for the treatment of sarcopenia has beneficial effects on muscle function and increases muscle strength and mobility in animal models. It activates the MAS receptor in muscle cells, a key component of the Renin-Angiotensin System (RAS).
Novartis “breakthrough” drug bimagrumab is currently being evaluated for the treatment of sarcopenia and has demonstrated good safety and efficacy profile in phase III trials. Bimagrumab is a human monoclonal antibody that binds to type II activin receptors and prevents the binding of its ligands (e.g., myostatin, activin A). These ligands normally act as inhibitors of muscle growth and protein anabolism; bimagrumab lifts this inhibition and can increase muscle mass in young and older adults.
Further product details are provided in the report……..
Sarcopenia: Therapeutic Assessment
This segment of the report provides insights about the different Sarcopenia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Sarcopenia
There are approx. 10+ key companies which are developing the therapies for Sarcopenia. The companies which have their Sarcopenia drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Novartis and others.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Sarcopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Sarcopenia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sarcopenia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sarcopenia drugs.
Sarcopenia Report Insights
- Sarcopenia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Sarcopenia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Sarcopenia drugs?
- How many Sarcopenia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sarcopenia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sarcopenia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Sarcopenia and their status?
- What are the key designations that have been granted to the emerging drugs?